Drugs /

succimer

Back to Drugs List

Overview

NCI Definition [1]:
An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210.

Clinical Trials

View Clinical Trials for succimer

Succimer has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating succimer, 1 is phase 1 (1 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for succimer clinical trials.

Acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndromes are the most common diseases being investigated in succimer clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Succimer
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating succimer and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
meso-2,3-dimercaptobernsteinsäure, butanedioic acid, 2,3-dimercapto-, (r*,s*)-isomer, chemet, succimer, dmsa, meso 2, 3-dimercaptosuccinic acid, succimer (substance), acid, meso-dimercaptosuccinic, meso-dimercaptosuccinic acid, butanedioic acid, 2,3-dimercapto-, (2r,3s)-rel-, butanedioic acid, 2,3-dimercapto-, (r*,s*)-, meso dimercaptosuccinic acid, succimer [chemical/ingredient], meso-2,3-dimercaptosuccinic acid, meso-dimercaptosuccinic acid, succimer (product)
NCIT ID [1]:
C61953
SNOMED ID [1]:
C-B8018

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.